Anagliptin - Sanwa Kagaku Kenkyusho/Kowa Pharmaceutical
Alternative Names: Beskoa; CWP-0403; SK-0403; SuinyLatest Information Update: 02 Oct 2021
At a glance
- Originator Kyowa Hakko; Sanwa Kagaku Kenkyusho
- Developer JW Pharmaceutical; Kowa Pharmaceutical; Sanwa Kagaku Kenkyusho
- Class Antihyperglycaemics; Nitriles; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 05 Mar 2019 No development reported - Phase-III for Type 2 diabetes mellitus in South Korea (PO)
- 04 Mar 2019 Anagliptin is still in phase II trials for Type 2 diabetes mellitus in USA and EU (Kowa Pharmaceutical pipeline, March 2019)
- 21 Nov 2018 Sanwa Kagaku Kenkyusho and Yokohama City University complete a phase II trial for Type 2 diabetes mellitus in Japan (PO) (UMIN000021494)